Detail akcie Calidi Bio Rg online

Business Summary: Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Calidi Biotherapeutics Inc revenues was not reported. Net loss decreased 31% to $5M. Lower net loss reflects Biotechnology & Medical Research segment loss decrease of 25% to $5.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$24.39 to -$2.21.